Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 14/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227167 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL30227142 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL23992208 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL30227089 | 0.84 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL23992207 | 0.84 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL30227135 | 0.78 | HDAC3 (0.63) | HDAC3HDAC1HDAC2 | |
| SCHEMBL26049179 | 0.78 | HDAC3 (0.63) | HDAC3HDAC1HDAC2 | |
| SCHEMBL24086714 | 0.77 | HDAC1 (0.61) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL30227367 | 0.76 | HDAC1 (0.82) | HDAC3HDAC1HDAC2NCOR2NAMPT | |
| SCHEMBL24086663 | 0.76 | HDAC1 (0.82) | HDAC3HDAC1HDAC2NCOR2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-08-24 | — | — | US | disclosed |
| US-11672788-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2023-06-13 | — | — | US | disclosed |
| US-20210379032-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2021-12-09 | — | — | US | disclosed |
| WO-2021219040-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | GNT BIOTECH & MEDICALS CORPORATION (CN) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379032-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
| US-11672788-B2 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
| US-20230263790-A1 | HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT | HDAC1, HDAC2, HDAC9 | HDAC3 5/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.